Paclitaxel-eluting stents

Future Cardiology

Volumn 2, Issue 2, 2006, Pages 229-239

  Cosgrave, John ^a   Simon, Corbett ^a   Babic, Rade ^a   Colombo, Antonio ^a  

^a EMO GVM CENTRO CUORE COLUMBUS   (Italy)

Author keywords

Major adverse cardiac events; Paclitaxel eluting stent; Restenosis; Revascularization

Indexed keywords

PACLITAXEL;

ABSENCE OF SIDE EFFECTS; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG MECHANISM; DRUG STRUCTURE; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTATION; MEDICAL INSTRUMENTATION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHENOMENOLOGY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; SURGICAL TECHNIQUE;

EID: 33646597258     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.2.229     Document Type: Review

References (34)

1. Manfredi JJ, Horwitz SB: Taxol: an antimitotic agent with a new mechanism of action. Pharmacol. Ther. 25, 83-125 (1984).
2. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N. Engl. J. Med. 332, 1004-1014 (1995).
3. Horwitz SB, Lothstein L, Manfredi JJ et al.: Taxol: mechanisms of action and resistance. Ann. NY Acad. Sci. 466, 733-44 (1986).
4. Axel DI, Kunert W, Goggelmann C et al.: Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96, 636-645 (1997).
5. Farb A, Heller PF, Shroff S et al.: Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104, 473-479 (2001).
6. Drachman DE, Edelman ER, Seifert P et al.: Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 36, 2325-2332 (2000).
7. Grube E, Silber S, Hauptmann KE et al.: TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Cirrulation 107(1), 38-42 (2003).
8. Grube E, Silber S, Hauptmann KE et al.: Two-year plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I) Am. J. Cardiol. 96(1), 79-82 (2005).
9. Colombo A, Drzewiecki J, Banning A et al.: Randomized study to assess the effectiveness of slow and moderate-release polymer based paclitaxel-eluting stents for coronary artery lesions. Cirulation 108, 788-794 (2003).
10. Colombo A: TAXUS II International trial: 2-year results. Presented at the Scientific Sessions of the Transcatheter Cardiovascular Therapeutics. Washington DC, 27 September - 1 October 2004.
11. Serruys PW, Degertekin M. Tanabe K et al for the TAXUS II Study Group: Vascular responses at proximal and distal edges of paclitaxel-eluting stents serial intravascular ultrasound analysis from the TAXUS II Trial. Circulation 109, 627-633 (2004).
12. Tanabe K, Serruys PW, Grube E. et al.: TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 107, 559-564 (2003).
13. Stone GW, Ellis SG, Cox DA et al.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350, 3, 2221-2231.
14. Stone GW, Ellis SG, Cox DA et al.: One year clinical results with the slow-release, polymer based, paclitaxel-eluting TAXUS stent. The TAXUS IV trial. Circulation 109, 1942-1947 (2004).
15. Stone GW, Ellis SG, Cannon L et al.: Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. JAMA 294, 1215-1223 (2005).
16. Dawkins KD, Grube E, Guagliumi G et al on behalf of the TAXUS VI investigators: Clinical efficacy of polymer based paclitaxel eluting stents in the treatment of complex, long lesions from a multicentre, randomized trial: support for the use of drug eluting stents in contemporary clinical practice. Circulation 112(21), 3306-3313 (2005).
17. Grube E: TAXUS VI, a randomized trial of moderate rate release polymer-based paclitaxel-eluting TAXUS stent for the treatment of longer lesions: 9-month clinical results. Presented at the Scientific Sessions of the Paris Course on Revascularization, Paris France, 25-28 May 2004.
18. Grube E: TAXUS VI, A randomized trial of moderate rate release polymer-based paclitaxel-eluting TAXUS stent for the treatment of longer lesions: 2 year clinical results. Presented at the Scientific Sessions of the Paris Course on Revascularization, Paris, France, 25-27 May 2005.
19. Abizaid A, Chan C. LIM YT et al.: WISDOM high-risk subgroups: 12-month outcomes with the slow-release, polymer-based, paclitaxel-eluting TAXUS stents. Am. J Cardiol. 94 (Suppl. 6A), 70E (2004).
20. Störger H: MILESTONE II, a global observational registry with TAXUS express coronary stent system. Presented at the Scientific Sessions of the Paris Course on Revascularization, Paris, France, 24-27 May 2005.
21. Lasala JM: ARRIVE, A consecutive enrolling drug eluting stent registry, 6 month results. Presented at the Scientific Sessions of the Paris Course on Revascularization, Paris, France, May 2005.
22. Sangiorgi G, Michev I, Grube E et al.: Unrestricted utilization of paclitaxel- polymer stents in routine interventional practice treating complex coronary lesions: results from the TRUE registry. Am. J. Cardiol. 94(Suppl 6A), 207E (2004).
23. GrubeE, Lanskt A, Hauptmann KE et al.: High-does 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE reandomized trial. J. Am. Coll. Cardiol. 44(7), 1368-1372 (2004).
24. Park SJ, Shim WH, Ho DS et al.: A paclitaxel-eluting stent for the prevention of coronary restenosis. N. Engl. J. Med. 348, 16, 1537-1545 (2003).
25. Gershlik A, De Scheerder I, Chevalier B et al.: Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: The European evaluation of paclitaxel eluting stent (ELUTES) trial. Circulation 109, 487-493 (2004).
26. Lansky AJ, Costa RA, Mintz GS et al.: Non-polymer based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 109, 1948-1954 (2004).
27. Gambhir DS: The infinium polymer-based paclitaxel drug-eluting stent: results from real world clinical trials. Presented at the Scientific Sessions of the Transcatheter Cardiovascular Therapeutics, Washington DC, 27 September - 1 October, 2004.
28. Finkelstein A, McClean D, Kar S et al.; Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 107, 777-784 (2003).
29. Serruys PW, Sianos G, Abizaid A et al.; The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform. J. Am. Coll. Cardiol. 46, 253-260 (2005).
30. Serruys PW: The new Costar stent: 12 month results with the new DES technology. Presented at the Scientific Sessions of the Paris Course on Revascularization, Paris, France, 24-27 May 2005.
31. Dawkins KD:. European Cobalt Stent with Antiproliferative for Restenosis Trial. Presented at the Scientific Sessions of the Paris Course on Revascularization, Paris, France, 24-27 May 2005.
32. Turco MA: TAXUS ATLAS: 30-day results. Prasented at the Scientific Sessions of the Paris Course on Revascularization, Paris, France, 24-27 May 2005.
33. Moreno R, Fernández C, Hernández R et al.: Drug-eluting stent thrombosis results from a pooled analysis including 10 randomized studies. J. Am. Coll. Cardiol. 45(6), 954-959 (2005).
34. Iakovou I, Schmidt T, Bonizzoni E et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293, 2154-2156 (2005).